Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash & Equivalents (2023 - 2025)

CG Oncology (CGON) has disclosed Cash & Equivalents for 3 consecutive years, with $32.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 87.36% year-over-year to $32.5 million, compared with a TTM value of $32.5 million through Dec 2025, down 87.36%, and an annual FY2025 reading of $32.5 million, down 87.36% over the prior year.
  • Cash & Equivalents was $32.5 million for Q4 2025 at CG Oncology, down from $45.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $257.1 million in Q4 2024 and bottomed at $8.3 million in Q4 2023.
  • Average Cash & Equivalents over 3 years is $60.6 million, with a median of $41.5 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents soared 3009.94% in 2024, then plummeted 87.36% in 2025.
  • Year by year, Cash & Equivalents stood at $8.3 million in 2023, then skyrocketed by 3009.94% to $257.1 million in 2024, then tumbled by 87.36% to $32.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for CGON at $32.5 million in Q4 2025, $45.1 million in Q3 2025, and $14.6 million in Q2 2025.